Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann J T, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C
Primary Institution: Department of Hematology/Oncology, University of Tuebingen Medical Center
Hypothesis
To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma.
Conclusion
The combination of paclitaxel, cisplatin, and continuously infused 5-FU/folinic acid is a highly active treatment for advanced gastric cancer.
Supporting Evidence
- Five patients (11%) achieved a complete response.
- Eighteen patients (40%) achieved a partial response.
- The overall response rate was 51%.
- The median progression-free survival time was 9 months.
- The median overall survival time was 14 months.
Takeaway
This study tested a new combination of cancer drugs on patients with advanced stomach cancer and found it worked well for many of them.
Methodology
Patients received a combination of paclitaxel, cisplatin, and 5-FU/folinic acid over several cycles, with assessments for response, survival, and toxicity.
Limitations
The study had a small sample size and was limited to patients who were chemotherapy-naive.
Participant Demographics
Forty-five chemotherapy-naive patients, 28 male and 17 female, with a median age of 60 years.
Statistical Information
Confidence Interval
95% CI: 35.8–66.3%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website